According to a recent LinkedIn post from Andelyn Biosciences, the company is partnering with Evolyra Therapeutics to advance gene therapies targeting Limb-Girdle Muscular Dystrophies subtypes LGMDR3 and LGMDR5. The post indicates that Andelyn’s AAV Curator® Platform will be used for clinical AAV manufacturing to support IND-enabling studies and planned clinical trials.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The LinkedIn post highlights that Evolyra’s muscle-targeting vector technology has shown promising preclinical results in these rare, progressive diseases, which currently have no cure. For investors, this collaboration suggests pipeline expansion in rare neuromuscular indications, potential long-term value from high-need orphan markets, and increased demand for Andelyn’s specialized manufacturing capabilities, though timelines and commercial outcomes remain uncertain.